Connor Clark & Lunn Investment Management Ltd. Takes $4.27 Million Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 3rd quarter, Holdings Channel reports. The fund bought 235,062 shares of the life sciences company’s stock, valued at approximately $4,271,000.

Other large investors have also added to or reduced their stakes in the company. Boston Partners acquired a new position in Integra LifeSciences in the 1st quarter worth $19,383,000. Cooke & Bieler LP lifted its stake in shares of Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after acquiring an additional 388,710 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after purchasing an additional 335,557 shares during the last quarter. Systematic Financial Management LP grew its stake in Integra LifeSciences by 540.6% during the 2nd quarter. Systematic Financial Management LP now owns 397,474 shares of the life sciences company’s stock valued at $11,582,000 after purchasing an additional 335,424 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Integra LifeSciences by 90.9% in the 2nd quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company’s stock valued at $17,436,000 after purchasing an additional 291,326 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Trading Up 2.5 %

Shares of NASDAQ IART opened at $23.58 on Friday. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -262.00, a price-to-earnings-growth ratio of 0.78 and a beta of 1.08. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock’s 50 day simple moving average is $20.08 and its 200 day simple moving average is $24.03.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. Equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Bank of America decreased their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, JMP Securities decreased their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.